Drug Trial Radar · NCT07328022
Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
May 14, 2025
Primary completion
Aug 20, 2025
Study completion Nov 19, 2025
Sponsor
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III, multicenter, prospective, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib/betamethasone compared with etoricoxib alone in patients with an acute episode of bursitis, tendinitis, or synovitis affecting the shoulder, elbow, knee, or ankle.
Conditions
- Bursitis
- Tendinitis
- Synovitis
Interventions
Fixed Dose Etoricoxib + BetamethasoneDrug
One tablet of 90 mg / 0.25 mg a day, for 14 days
Monotherapy EtoricoxibDrug
One tablet aog 90 mg a day, for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pain during active movement of the affected joint (VAS 100 mm) at Days 3, 7, 10, and 14 vs baseline, by treatment group.Time frame: Baseline and Days 3, 7, 10, and 14
- Number of participants with adverse events, and comparison of adverse event frequency and intensity, by treatment group.Time frame: Up to 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laboratorios Silanes, S.A. de C.V.
Mexico City, Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.